CASI Pharmaceutical Signs an Exclusive Worldwide License Agreement with Black Belt for its TSK011010 Program

 CASI Pharmaceutical Signs an Exclusive Worldwide License Agreement with Black Belt for its TSK011010 Program

CASI Pharmaceutical Signs an Exclusive Worldwide License Agreement with Black Belt for its TSK011010 Program

Shots:

  • Black Belt to get $5.64M (€5M) upfront, equity investment of $2.26M (€2M), milestones and royalties on sales. CASI to get exclusive WW rights to develop and commercialize Black Belt’s anti-CD38 monoclonal antibody (Mab) TSK011010 program
  • The equity investment of $2.26M will be in a newly built subsidiary of Black Belt focusing on novel immuno-oncology targets
  • Anti-CD38 Mab program TSK011010 is an IgG1 mAb developed to activate effector T cells and NK cells and will be evaluated in P-I with expected onset in H2’19 or H1’20

Click here to read full press release/ article | Ref: Casi Pharmaceuticals | Image: Casi Pharmaceuticals

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post